Grandfield & Dodd LLC Reduces Stock Position in Stryker Corporation $SYK

Grandfield & Dodd LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.5% during the second quarter, Holdings Channel reports. The firm owned 98,058 shares of the medical technology company’s stock after selling 513 shares during the quarter. Stryker makes up about 2.3% of Grandfield & Dodd LLC’s investment portfolio, making the stock its 15th biggest position. Grandfield & Dodd LLC’s holdings in Stryker were worth $38,795,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Burling Wealth Partners LLC raised its holdings in shares of Stryker by 28.2% during the second quarter. Burling Wealth Partners LLC now owns 8,722 shares of the medical technology company’s stock valued at $3,451,000 after acquiring an additional 1,916 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its position in shares of Stryker by 6.8% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 65,670 shares of the medical technology company’s stock valued at $25,968,000 after buying an additional 4,204 shares during the period. Brogan Financial Inc. bought a new position in shares of Stryker in the 2nd quarter worth approximately $212,000. WASHINGTON TRUST Co grew its position in shares of Stryker by 1.6% in the 2nd quarter. WASHINGTON TRUST Co now owns 53,419 shares of the medical technology company’s stock worth $21,134,000 after buying an additional 835 shares during the period. Finally, ABN Amro Investment Solutions bought a new position in shares of Stryker in the 2nd quarter worth about $67,210,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on SYK. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Evercore ISI reduced their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Barclays lifted their price objective on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. UBS Group set a $408.00 price target on shares of Stryker in a report on Monday, October 13th. Finally, Truist Financial reissued a “hold” rating and set a $392.00 price objective (down from $407.00) on shares of Stryker in a report on Monday, November 3rd. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $433.37.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This trade represents a 9.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 520,500 shares of company stock worth $184,803,065 over the last quarter. 5.20% of the stock is owned by company insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $372.93 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $142.62 billion, a PE ratio of 49.40, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The firm’s 50 day moving average price is $372.55 and its 200-day moving average price is $381.18. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.